Orthopedic Surgery

Consensus guideline sharpens operative decision-making for acute Achilles tendon rupture

A steering committee of 40 orthopedic surgeons produced nine evidence-based recommendations for surgical management of acute Achilles tendon rupture. The guideline endorses surgery as a reliable option when aiming to restore function, emphasizing meticulous operative planning and rehab pathways. It directly addresses controversies around indications, timing, positioning, open versus minimally invasive techniques, augmentation, and postoperative protocols. The authors stress that postoperative rehabilitation remains insufficiently standardized and call for structured, evidence-based regimens. They also note that nutraceuticals, biomaterials, cellular and gene therapies, and anti-inflammatory agents are still experimental in this setting. 1

Digital and electromechanical rehab after arthroplasty yields small but meaningful functional gains

This systematic review and meta-analysis included 15 low-risk-of-bias RCTs comparing technology-enabled rehabilitation with usual care after lower-limb arthroplasty. Across 1,012 experimental and 954 control participants, tech-enabled rehab provided a small but statistically significant improvement in patient-reported function (Hedges g 0.28). Virtual-reality platforms showed the largest point estimate of benefit, while web or app-based and robot or sensor systems provided modest, non-significant advantages. Heterogeneity was substantial, implying that dose, feedback fidelity, and sensor precision likely drive outcomes. The authors conclude that these programs are at least non-inferior to usual care and can reduce in-person therapist time. 2

Denosumab modestly lowers incident knee OA risk versus bisphosphonates in osteoporosis

This new-user, active-comparator cohort used electronic health records to compare denosumab with bisphosphonates for incident osteoarthritis in osteoporosis patients. After propensity-score matching, 59,157 denosumab users were compared with 59,157 bisphosphonate users, mean age 70 years and predominantly female. Ten-year knee OA incidence was lower with denosumab than bisphosphonates, while hip OA incidence was similar between groups. Overall OA risk was slightly reduced with denosumab (HR 0.96), with a more pronounced reduction for knee OA (HR 0.87). Risk reductions were stronger among older adults, women, and Asian individuals, supporting hypothesis-generating subgroup signals. 3